

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Gram-negative bacterial infection	Capsular polysaccharide export protein (wza)	Cell culture studies identified a glycomimetic inhibitor of wza that could help treat Gram-negative bacterial infections. An <i>in vitro</i> screen identified an unnatural cyclic glycomimetic that could inhibit wza activity by blocking the protein's α -helix barrel. In a pathogenic strain of <i>Escherichia coli</i> cultured in human serum, the glycomimetic blocked the transport of a capsular polysaccharide and caused defects in the bacterial outer membrane, and it increased complement-mediated killing of bacteria compared with no treatment. Next steps include evaluating the glycomimetic in animal models.	Patent application filed; available for licensing from Isis Innovation Ltd. Contact: Mark Gostock, Isis Innovation Ltd., Oxford, U.K. e-mail: mark.gostock@isis.ox.ac.uk	Kong, L. <i>et al. Nat. Chem.</i> ; published online June 30, 2013; doi:10.1038/nchem.1695 Contact: Hagen Bayley, University of Oxford Chemical Research Laboratory, Oxford, U.K. e-mail: hagan.bayley@chem.ox.ac.uk Contact: Benjamin G. Davis, same affiliation as above e-mail: ben.davis@chem.ox.ac.uk
<p><i>SciBX</i> 6(29); doi:10.1038/scibx.2013.761 Published online Aug. 1, 2013</p>				